{"id":"trivalent-sub-unit-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10–20","effect":"Injection site soreness or erythema"},{"rate":"5–10","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Low-grade fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The trivalent sub-unit influenza vaccine contains purified surface antigens (hemagglutinin and neuraminidase) from three influenza virus strains (typically two A strains and one B strain). These non-infectious protein subunits trigger both humoral and cell-mediated immune responses, enabling the body to recognize and neutralize circulating influenza viruses before infection occurs.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:42.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza infection caused by influenza A and B viruses"}]},"trialDetails":[{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":"Influenza, HIV, Tuberculosis","enrollment":301},{"nctId":"NCT00644540","phase":"PHASE2","title":"Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"FLU","enrollment":89},{"nctId":"NCT01210898","phase":"PHASE3","title":"Immunogenicity and Safety of V70P5 Revaccination Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Influenza","enrollment":197},{"nctId":"NCT01152814","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Seasonal Influenza","enrollment":64},{"nctId":"NCT00962715","phase":"PHASE1, PHASE2","title":"Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04","conditions":"Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT00883012","phase":"PHASE4","title":"Influenza Vaccine in HIV Infected Children","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2009-02","conditions":"Influenza With Pneumonia, Influenza Virus Identified","enrollment":412},{"nctId":"NCT01357265","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Influenza","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Trivalent sub-unit influenza vaccine","genericName":"Trivalent sub-unit influenza vaccine","companyName":"University of Witwatersrand, South Africa","companyId":"university-of-witwatersrand-south-africa","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus. Used for Prevention of influenza infection caused by influenza A and B viruses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}